Soft Tissue Sarcoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Soft Tissue Sarcoma Pipeline Insight 2024" report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from Soft Tissue Sarcoma Pipeline Report

* DelveInsight's Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
* The leading Soft Tissue Sarcoma Companies working in the market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
* Promising Soft Tissue Sarcoma Pipeline Therapies in the various stages of development include Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.
* May 2024:- Institut Claudius Regaud- Phase I Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma. This is a phase I, multicenter, open-label study starting with a dose exploration phase and followed by an expansion phase to evaluate the safety profile and the preliminary activity of the bispecific antibody anti PD-1/CTLA-4 MEDI5752 in combination with SBRT delivered on one lung metastatic lesion, in patients with metastatic soft tissue sarcoma.

Request a sample and discover the recent advances in Soft Tissue Sarcoma @ Soft Tissue Sarcoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Soft Tissue Sarcoma Overview

Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy. Soft-tissue sarcomas are a group of cancers that begin in the connective tissues that support and connect the body, including: Blood vessels, Fat cells, Lining of joints, Lymph vessels, Muscle, Nerves and Tendons. As a result, soft-tissue sarcomas can occur almost anywhere in the body.

The Soft Tissue Sarcoma treatment options and prognosis depend on the following: The type of soft tissue sarcoma, the size, grade, and stage of the tumor, where the tumor is in the body, whether all of the tumor is removed by surgery, the patient's age and general health and whether the cancer has recurred (come back). Small, low-grade tumors, especially in the trunk, arms, or legs, are frequently treated with surgery alone. High-grade sarcomas are more difficult to treat and more likely to spread.

Soft Tissue Sarcoma Emerging Drugs

* AL3818: Advenchen Laboratories

Anlotinib was developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. as a new oral molecular RTK inhibitor; it targets VEGFR1, VEGFR3, VEGFR2/KDR, PDGFR-, c-Kit, and FGFRs 1-3 and inhibits TA and tumor cell proliferation. Anlotinib may inhibit more targets than that do other RTK inhibitors, such as pazopanib, sunitinib, and sorafenib. The main mechanisms of action of anlotinib are as follows: preclinical studies have shown that anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration, angiogenesis, and capillary-like tube formation in endothelial cells.

* L19 TNF: Philogen

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications). The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses.

* Camsirubicin: Monopar Therapeutics

Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types.

Learn more about Soft Tissue Sarcoma in clinical trials @ Soft Tissue Sarcoma Drugs [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Soft Tissue Sarcoma Therapeutics Assessment

There are approx. 125+ key Soft Tissue Sarcoma companies which are developing the therapies for Soft Tissue Sarcoma. The Soft Tissue Sarcoma companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.

DelveInsight's Soft Tissue Sarcoma pipeline report covers around 130+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Soft Tissue Sarcoma in development @ Soft Tissue Sarcoma Clinical Trials [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Soft Tissue Sarcoma Companies

Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

To know more about Soft Tissue Sarcoma, visit @ Soft Tissue Sarcoma Segmentation [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Soft Tissue Sarcoma Pipeline Report

* Coverage- Global
* Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
* Soft Tissue Sarcoma Pipeline Therapies- Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.

For further information on the Soft Tissue Sarcoma Pipeline Therapeutics, reach out @ Soft Tissue Sarcoma Products Development [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Soft Tissue Sarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Anlotinib: Advenchen Laboratories, LLC
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Camsirubicin: Monopar Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* FHD-609: Foghorn Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Soft Tissue Sarcoma Key Companies
* Soft Tissue Sarcoma Key Products
* Soft Tissue Sarcoma- Unmet Needs
* Soft Tissue Sarcoma- Market Drivers and Barriers
* Soft Tissue Sarcoma- Future Perspectives and Conclusion
* Soft Tissue Sarcoma Analyst Views
* Soft Tissue Sarcoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=soft-tissue-sarcoma-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.